For the fiscal quarter ending June 30, 2026, Cybin Inc. is expected to report a consensus EPS loss of -$0.80 on zero revenue, with shares currently trading at $11.61 against an average analyst price target of $34.00.
Investors are primarily focused on the clinical progress of HLP003, the company's lead psilocybin analog, following the successful completion of enrollment in the pivotal Phase 3 APPROACH trial for major depressive disorder.
This reporting cycle follows the strategic appointment of Michael Halstead as CEO, which has signaled a shift toward late-stage commercialization and potential M&A optionality.
Analysts will also scrutinize the company's cash runway and burn rate to ensure sufficient funding through the anticipated topline data readouts in late 2026.